Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE, Prieto González JM, Caminero Rodríguez AB, Olascoaga Urtaza J, Alonso AM, Durán Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Pérez Ruiz D, Calles C, Hernández MA, Hervás García M, Mendoza Rodríguez A, Berdei Montero Y, Téllez N, Herrera Varó N, Sotoca J, Presas-Rodríguez S, Querol Gutierrez LA, Hervás Pujol M, Batlle Nadal J, Martín Ozaeta G, Gubieras Lillo L, Martínez Yélamos S, Ramió-Torrentà L, Mallada Frechin J, Belenguer Benavides A, Gascón-Giménez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gómez Gutierrez M, Durán C, Rodríguez Regal A, Álvarez E, García-Estévez DA, López Real AM, Llaneza González MA, Marzo Sola ME, Sánchez-Menoyo JL, Oterino A, Villaverde González R, Castillo-Triviño T, Álvarez de Arcaya A, Llarena C. Meca-Lallana JE, et al. Among authors: rodriguez regal a. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. Neurol Ther. 2023. PMID: 37861931 Free PMC article.
Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.
Sainz de la Maza S, Maurino J, Castillo-Triviño T, Borges M, Sebastián Torres B, Sotoca J, Alonso Torres AM, Caminero AB, Borrega L, Sánchez-Menoyo JL, Barrero-Hernández FJ, Calles C, Brieva L, Blasco MR, Dotor García-Soto J, Rodríguez-Regal A, Navarro-Cantó L, Agüera-Morales E, Garcés M, Carmona O, Gabaldón-Torres L, Forero L, Hervás M, Gómez-Ballesteros R. Sainz de la Maza S, et al. Among authors: rodriguez regal a. Patient Prefer Adherence. 2023 Jun 14;17:1431-1439. doi: 10.2147/PPA.S411069. eCollection 2023. Patient Prefer Adherence. 2023. PMID: 37337517 Free PMC article.
Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
López-Real AM, Gonzalez I, Solar DM, Oterino A, Costa E, Pato A, Llaneza MA, García-Estévez DA, Rodriguez-Regal A, Rodriguez M, Peña J. López-Real AM, et al. Among authors: rodriguez regal a. Mult Scler Relat Disord. 2023 Jul;75:104762. doi: 10.1016/j.msard.2023.104762. Epub 2023 May 13. Mult Scler Relat Disord. 2023. PMID: 37229800
[Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Galicia].
Pato-Pato A, Midaglia L, Costa-Arpin E, Rodriguez-Regal A, Puy-Nunez A, Rodriguez-Rodriguez M, Lopez-Real A, Llaneza-Gonzalez MA, Garcia-Estevez DA, Moreno-Carretero MJ, Escriche-Jaime D, Aguado-Valcarcel ML, Munoz D, Prieto JM, Lorenzo-Gonzalez JR, Amigo-Jorrin MC. Pato-Pato A, et al. Among authors: rodriguez regal a. Rev Neurol. 2016 Sep 5;63(s01):S13-S18. Rev Neurol. 2016. PMID: 27658431 Spanish.
[No title available]
[No authors listed] [No authors listed] PMID: 29754703
Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.
Pato Pato A, Costa Arpín E, Rodríguez Regal A, Rodríguez Constenla I, Cimas Hernando I, Muñoz Pousa I, Naya Ríos L, Lorenzo González JR, Amigo Jorrín MC, Prieto González JM. Pato Pato A, et al. Among authors: rodriguez regal a. Neurologia (Engl Ed). 2021 Jun;36(5):346-352. doi: 10.1016/j.nrleng.2020.02.001. Epub 2020 Feb 16. Neurologia (Engl Ed). 2021. PMID: 34714232 Free article.
Clinical response and tolerability of fampridine in clinical practice.
Costa-Arpín E, Pato A, Rodríguez-Regal A, Midaglia L, Yáñez R, Muñoz D, Lorenzo JR, Amigo C, Prieto JM. Costa-Arpín E, et al. Among authors: rodriguez regal a. Neurodegener Dis Manag. 2016 Apr;6(2):99-105. doi: 10.2217/nmt-2015-0004. Epub 2016 Apr 1. Neurodegener Dis Manag. 2016. PMID: 27032814
[Clinical experience with lacosamide in Galicia: the GALACO study].
Rodriguez-Osorio X, Lopez-Gonzalez FJ, Pato-Pato A, Cebrian-Perez E, Marey-Lopez J, Corredera-Garcia E, Rubio-Nazabal E, Castro-Vilanova MD, Abella-Corral J, Rodriguez-Regal A, Amigo-Jorrin MC, Pego-Reigosa R; en representación del grupo de estudio GALACO. Rodriguez-Osorio X, et al. Among authors: rodriguez regal a. Rev Neurol. 2015 Dec 16;61(12):536-42. Rev Neurol. 2015. PMID: 26662871 Free article. Spanish.
17 results